We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NIH/NCI Renews and Expands Nation-Wide License for Genomatix Software and Databases
News

NIH/NCI Renews and Expands Nation-Wide License for Genomatix Software and Databases

NIH/NCI Renews and Expands Nation-Wide License for Genomatix Software and Databases
News

NIH/NCI Renews and Expands Nation-Wide License for Genomatix Software and Databases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NIH/NCI Renews and Expands Nation-Wide License for Genomatix Software and Databases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genomatix Software Inc., the newly incorporated subsidiary of Genomatix Software GmbH, has announced that it has renewed and extended its software licensing agreement with the NCI/NIH for the fourth consecutive year.

This year’s renewal marks a benchmark in the company’s history as the renewal was executed entirely between the US company and the NCI/NIH campus in Bethesda, MD.

“We are extremely pleased with our progress in putting the US company on its feet, and the renewal with NCI/NIH is a huge step in firmly establishing our presence here”, said Peter Grant, CEO of the US company.

 “Our mission is to expand the presence of Genomatix and its capabilities for understanding gene regulation in North America, and NCI/NIH have clearly gotten the message. Their renewal has grown with us each year, and this year represents the biggest increase yet.”

Klaus May, Chief Business Officer of the Munich based company and Board Chairman of the US company commented: “Genomatix realized several years ago that to properly service the North American market, you needed a North American presence.

We have already seen significant gains in the short time since the US operation was established, and the increase in the NCI/NIH renewal accurately reflects the wisdom of that decision. We are very pleased with the rapid progress the US company has made in growing the business and expanding the awareness of our product.”

Genomatix is a pioneer and leader in the analysis and understanding of eukaryotic gene regulation. Core competences at Genomatix are annotation driven microarray analysis, ChIP on chip, regulatory network and pathway mining, and promoter analysis on sequence level.

Genomatix has published more than 170 peer reviewed scientific papers that have been cited in more than 4,000 papers. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.

Advertisement